(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 106.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Prothena Public Co's revenue in 2026 is $11,786,000.On average, 9 Wall Street analysts forecast PRTA's revenue for 2026 to be $7,797,272,893, with the lowest PRTA revenue forecast at $5,275,338,236, and the highest PRTA revenue forecast at $14,412,977,681. On average, 6 Wall Street analysts forecast PRTA's revenue for 2027 to be $1,830,219,388, with the lowest PRTA revenue forecast at $0, and the highest PRTA revenue forecast at $5,652,148,110.
In 2028, PRTA is forecast to generate $5,549,871,144 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $8,608,490,721.